EMA Authorised: Bonviva (ibandronic acid) — Atnahs Pharma Netherlands B.V.

View source ↗

Summary

The EMA authorised Bonviva (ibandronic acid) for osteoporosis, including postmenopausal osteoporosis. The marketing authorization holder is Atnahs Pharma Nether…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Bonviva (ibandronic acid)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis, Postmenopausal. MAH: Atnahs Pharma Netherlands B.V.. Decision date: 25/01/2024